Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus Paclitaxel in Recurrent Metastatic Gastric or GEJ Adenocarcinoma
NCT05978050Phase 3Recruiting
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and esophagogastric junction adenocarcinoma (GEJA) comparing Nimotuzumab + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoint: Overall Survival at 18 months. Started Aug 2024; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05978050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978050.